Explore the Relationship Between the Percentage of Colonoscopy Withdrawal Overspeed and the ADR

Overview

In this study, the investigators used the optical flow method to measure the colonoscopy withdrawal speed, and doctors were selected from multiple hospitals to collect prospective colonoscopy screening videos, and the percentage of colonoscopy withdrawal overspeed was calculated to explore the relationship between it based on optical flow method and the adenoma detection rate.

Full Title of Study: “Explore the Relationship Between the Percentage of Colonoscopy Withdrawal Overspeed and the Adenoma Detection Rate: a Prospective, Multicenter, Observational Study”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: October 29, 2023

Detailed Description

Study showed that adequate withdrawal time is an important prerequisite for full mucosal inspection. In a large population-based analysis, a 1-min increase in withdrawal time led to a 3.6% increase in the ADR. Protocols or expert consensus recommend a standard withdrawal time of 6 min or longer. However, Findings of studies showed that a number of colonoscopies had a withdrawal time less than 6 min, which greatly reduces the ADR. Investigator's preliminary experiments have shown that deep learning can monitor the colonoscopy withdrawal time in real-time and improve the adenoma detection rate. Based on the above rich foundation of preliminary work and the massive demand for improving the colonoscopy withdrawal assessment system. The investigators improved EndoAngel to use optical flow method to monitor the colonoscopy withdrawal speed. The performance of the EndoAngel system was verified in colonoscopy videos. The investigators then aimed to evaluate whether the EndoAngel system could improve polyp detection rate after restricting the colonoscopy withdrawal speed.

Clinical Trial Outcome Measures

Primary Measures

  • The adenoma detection rate (ADR)
    • Time Frame: A month
    • ADR was calculated by dividing the total number of patients being detected adenomas by the number of colonoscopies.
  • The percentage of colonoscopy withdrawal overspeed
    • Time Frame: A month
    • The percentage of colonoscopy withdrawal overspeed was calculated by dividing the time of colonoscopy withdrawal overspeed by the total time of colonoscopy withdrawal.

Secondary Measures

  • The polyp detection rate (PDR)
    • Time Frame: A month
    • PDR was calculated by dividing the total number of patients being detected polyps by the number of colonoscopies.
  • The mean number of polyps per patient (MNP)
    • Time Frame: A month
    • MNP was calculated by dividing the total number of polyps by the number of colonoscopies.
  • The mean number of adenomas per patient (MAP)
    • Time Frame: A month
    • MAP was calculated by dividing the total number of adenomas by the number of colonoscopies.
  • colonoscopy withdrawal time
    • Time Frame: A month
    • The time is taken to finish the examination from the beginning of the ileocecal region.
  • colonoscopy forward time
    • Time Frame: A month
    • The time is taken to go from the rectum to the ileocecal region.

Participating in This Clinical Trial

Inclusion Criteria

1. Male or female ≥18 years old; 2. Able to read, understand and sign an informed consent; 3. The investigator believes that the subjects can understand the process of the clinical study, are willing and able to complete all study procedures and follow-up visits, and cooperate with the study procedures; 4. Patients requiring screening colonoscopy. Exclusion Criteria:

1. Have drug or alcohol abuse or mental disorder in the last 5 years; 2. Pregnant or lactating women; 3. Patients with known multiple polyp syndrome; 4. patients with known inflammatory bowel disease; 5. known intestinal stenosis or space-occupying tumor; 6. known colon obstruction or perforation; 7. patients with a history of colorectal surgery; 8. Patients with a previous history of allergy to pre-used spasmolysis; 9. Unable to perform biopsy and polyp removal due to coagulation disorders or oral anticoagulants; 10. High-risk diseases or other special conditions that the investigator considers the subject unsuitable for participation in the clinical trial.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Renmin Hospital of Wuhan University
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Contact(s)
    • Honggang Yu, Doctor, 8613871281899, yuhonggang@whu.edu.cn

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.